Editor of Patient Care Online.
Pegozafermin Receives Breakthrough Therapy Designation for Nonalcoholic Steatohepatitis
The US Food and Drug Administration granted BTD to pegozafermin for the treatment of patients with NASH.
Daily Dose: Dupilumab Potent Against Uncontrolled COPD with Type 2 Inflammation
Your daily dose of the clinical news you may have missed.
ACIP Recommends Maternal RSV Vaccine to Protect Newborns
Members of the ACIP voted on Friday to recommend Pfizer’s maternal bivalent RSVpreF vaccine to protect newborns from severe RSV illness.
Daily Dose: Early Childhood Obesity Treatment Found Effective Long-Term
Empagliflozin Wins FDA Approval for the Treatment of Adults with CKD
Empagliflozin is approved to lower the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression.
Daily Dose: Antihypertensive Treatment Throughout Late Life Lowers Risk of Dementia
Mental Health in the US: Happiest States in 2023
What state has highest share of adult depression? Or the lowest divorce rate? Find the answers and more insights from a nationwide analysis, here.
Daily Dose: Risky Alcohol Use Among US Adults Prescribed Alcohol-Interactive Medications
Early Initiation of Childhood Obesity Treatment Linked to Better Weight Outcomes Over Time
An intensive parent-support early childhood obesity intervention program led to better weight status outcomes in the long-term compared to standard therapy, report study authors.
Daily Dose: Parental Stigma Toward HPV Vaccine Barrier to Adolescent Uptake
Antiobesity Medications: Expert Compares Benefits, Drawback Among Classes
Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.
Daily Dose: Efficacy of a Remote Bilingual Program in Reducing Uncontrolled HTN
Antihypertensive Treatment Throughout Late Life May Reduce Risk of Dementia
Results from a new study show that older adults with untreated hypertension had a 42% increased risk of dementia vs healthy controls.
Daily Dose: High Blood Pressure While Lying Down Raises Risk for CVD Events
Daily Dose: More Steps a Day Linked to Better Health for Patients with Heart Failure
Your daily dose of clinical news you may have missed.
Antiobesity Medications: Expert Discusses Older, Newer Therapies
Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.
Daily Dose: COVID-19 Vaccination Decreases Symptoms of Long COVID
Remote Bilingual Program Proves Effective in Controlling Blood Pressure in Underserved Population
New research presented at Hypertension 2023 showed a novel digital bilingual hypertension control program improved BP control rates by more than 30%.
Daily Dose: Worldwide Burden of Atrial Fibrillation Doubled Over 30 Years
Hypertension While Lying Down Linked to Elevated Risk for CVD Events
Persons with HTN while in a supine position had a higher risk for CVD even if they did not have HTN while seated, according to new research presented at Hypertension 2023.
Daily Dose: DAPT Should Remain Gold Standard for Percutaneous Coronary Intervention
Daily Dose: Osteoarthritis Estimated to Affect Nearly 1 Billion by 2050
SSRI Treatment May Decrease Risk for Postnatal Depression-Associated Outcomes for Mother, Child
Results from a new study suggest that postnatal SSRI treatment may be beneficial in the long term for both women with postpartum depression and their children.
Daily Dose: Semaglutide 2.4 mg Benefits Patients with Heart Failure and Obesity
COVID-19 Vaccination May Decrease Symptoms of Long COVID, Report Mayo Clinic Researchers
Vaccination against SARS-CoV-2 may decrease the symptoms of post-COVID conditions, such as abdominal pain and weakness, according to new study.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Daily Dose: Aspirin for Secondary Prevention of Cardiovascular Disease
Dual Antiplatelet Therapy Should Remain Gold Standard for Percutaneous Coronary Intervention, Say Authors of New Study
ESC 2023: New data showed an aspirin-free strategy after PCI did not reduce major bleeding event risk vs DAPT, while omission of aspirin proved noninferior for CV events in high-risk patients.
Daily Dose: FDA Approves First Biosimilar for Multiple Sclerosis
Dapagliflozin Did Not Meet Primary Endpoint in DICTATE-AHF Trial of Patients with Acute Decompensated Heart Failure
ESC 2023: Early initiation of dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in patients hospitalized with ADHF.
